The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2

Z. Sheng Guo, Arpana Naik, Mark E. O'Malley, Petar Popovic, Richard Demarco, Yun Hu, Xiaoyu Yin, Shuting Yang, Herbert J. Zeh, Bernard Moss, Michael T. Lotze, David L. Bartlett

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The ability of cancer cells to evade apoptosis may permit survival of a recombinant vaccinia lacking antiapoptotic genes in cancer cells compared with normal cells. We have explored the deletion of two vaccinia virus host range/antiapoptosis genes, SPI-1 and SPI-2, for their effects on the viral replication and their ability to induce cell death in infected normal and transformed cells in vitro. Indeed, in three paired normal and transformed cell types, the SPI-1 and SPI-2 gene-deleted virus (vSP) preferentially replicates in transformed cells or p53-null cells when compared with their normal counterparts. This selectivity may be derived from the fact that vSP-infected normal cells died faster than infected cancer cells. A fraction of infected cells died with evidence of necrosis as shown by both flow cytometry and detection of high-mobility group B1 protein released from necrotic cells into the culture supernatant. When administered to animals, vSP retains full ability to replicate in tumor tissues, whereas replication in normal tissues is greatly diminished. In a model of viral pathogenesis, mice treated with vSP survived substantially longer when compared with mice treated with the wild-type virus. The mutant virus vSP displayed significant antitumoral effects in an MC38 s.c. tumor model in both nude (P <0.001) and immunocompetent mice (P <0.05). We conclude that this recombinant vaccinia vSP shows promise for oncolytic virus therapy. Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy.

Original languageEnglish (US)
Pages (from-to)9991-9998
Number of pages8
JournalCancer Research
Volume65
Issue number21
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Vaccinia
Host Specificity
Genes
Neoplasms
Viruses
Oncolytic Virotherapy
High Mobility Group Proteins
Null Lymphocytes
Vaccinia virus
Neoplasm Genes
Genetic Therapy
Flow Cytometry
Cell Death
Necrosis
Cell Culture Techniques
Apoptosis
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. / Guo, Z. Sheng; Naik, Arpana; O'Malley, Mark E.; Popovic, Petar; Demarco, Richard; Hu, Yun; Yin, Xiaoyu; Yang, Shuting; Zeh, Herbert J.; Moss, Bernard; Lotze, Michael T.; Bartlett, David L.

In: Cancer Research, Vol. 65, No. 21, 01.11.2005, p. 9991-9998.

Research output: Contribution to journalArticle

Guo, ZS, Naik, A, O'Malley, ME, Popovic, P, Demarco, R, Hu, Y, Yin, X, Yang, S, Zeh, HJ, Moss, B, Lotze, MT & Bartlett, DL 2005, 'The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2', Cancer Research, vol. 65, no. 21, pp. 9991-9998. https://doi.org/10.1158/0008-5472.CAN-05-1630
Guo, Z. Sheng ; Naik, Arpana ; O'Malley, Mark E. ; Popovic, Petar ; Demarco, Richard ; Hu, Yun ; Yin, Xiaoyu ; Yang, Shuting ; Zeh, Herbert J. ; Moss, Bernard ; Lotze, Michael T. ; Bartlett, David L. / The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. In: Cancer Research. 2005 ; Vol. 65, No. 21. pp. 9991-9998.
@article{1f7ba35ba51e4c65a64e121f4360ac89,
title = "The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2",
abstract = "The ability of cancer cells to evade apoptosis may permit survival of a recombinant vaccinia lacking antiapoptotic genes in cancer cells compared with normal cells. We have explored the deletion of two vaccinia virus host range/antiapoptosis genes, SPI-1 and SPI-2, for their effects on the viral replication and their ability to induce cell death in infected normal and transformed cells in vitro. Indeed, in three paired normal and transformed cell types, the SPI-1 and SPI-2 gene-deleted virus (vSP) preferentially replicates in transformed cells or p53-null cells when compared with their normal counterparts. This selectivity may be derived from the fact that vSP-infected normal cells died faster than infected cancer cells. A fraction of infected cells died with evidence of necrosis as shown by both flow cytometry and detection of high-mobility group B1 protein released from necrotic cells into the culture supernatant. When administered to animals, vSP retains full ability to replicate in tumor tissues, whereas replication in normal tissues is greatly diminished. In a model of viral pathogenesis, mice treated with vSP survived substantially longer when compared with mice treated with the wild-type virus. The mutant virus vSP displayed significant antitumoral effects in an MC38 s.c. tumor model in both nude (P <0.001) and immunocompetent mice (P <0.05). We conclude that this recombinant vaccinia vSP shows promise for oncolytic virus therapy. Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy.",
author = "Guo, {Z. Sheng} and Arpana Naik and O'Malley, {Mark E.} and Petar Popovic and Richard Demarco and Yun Hu and Xiaoyu Yin and Shuting Yang and Zeh, {Herbert J.} and Bernard Moss and Lotze, {Michael T.} and Bartlett, {David L.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-05-1630",
language = "English (US)",
volume = "65",
pages = "9991--9998",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2

AU - Guo, Z. Sheng

AU - Naik, Arpana

AU - O'Malley, Mark E.

AU - Popovic, Petar

AU - Demarco, Richard

AU - Hu, Yun

AU - Yin, Xiaoyu

AU - Yang, Shuting

AU - Zeh, Herbert J.

AU - Moss, Bernard

AU - Lotze, Michael T.

AU - Bartlett, David L.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - The ability of cancer cells to evade apoptosis may permit survival of a recombinant vaccinia lacking antiapoptotic genes in cancer cells compared with normal cells. We have explored the deletion of two vaccinia virus host range/antiapoptosis genes, SPI-1 and SPI-2, for their effects on the viral replication and their ability to induce cell death in infected normal and transformed cells in vitro. Indeed, in three paired normal and transformed cell types, the SPI-1 and SPI-2 gene-deleted virus (vSP) preferentially replicates in transformed cells or p53-null cells when compared with their normal counterparts. This selectivity may be derived from the fact that vSP-infected normal cells died faster than infected cancer cells. A fraction of infected cells died with evidence of necrosis as shown by both flow cytometry and detection of high-mobility group B1 protein released from necrotic cells into the culture supernatant. When administered to animals, vSP retains full ability to replicate in tumor tissues, whereas replication in normal tissues is greatly diminished. In a model of viral pathogenesis, mice treated with vSP survived substantially longer when compared with mice treated with the wild-type virus. The mutant virus vSP displayed significant antitumoral effects in an MC38 s.c. tumor model in both nude (P <0.001) and immunocompetent mice (P <0.05). We conclude that this recombinant vaccinia vSP shows promise for oncolytic virus therapy. Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy.

AB - The ability of cancer cells to evade apoptosis may permit survival of a recombinant vaccinia lacking antiapoptotic genes in cancer cells compared with normal cells. We have explored the deletion of two vaccinia virus host range/antiapoptosis genes, SPI-1 and SPI-2, for their effects on the viral replication and their ability to induce cell death in infected normal and transformed cells in vitro. Indeed, in three paired normal and transformed cell types, the SPI-1 and SPI-2 gene-deleted virus (vSP) preferentially replicates in transformed cells or p53-null cells when compared with their normal counterparts. This selectivity may be derived from the fact that vSP-infected normal cells died faster than infected cancer cells. A fraction of infected cells died with evidence of necrosis as shown by both flow cytometry and detection of high-mobility group B1 protein released from necrotic cells into the culture supernatant. When administered to animals, vSP retains full ability to replicate in tumor tissues, whereas replication in normal tissues is greatly diminished. In a model of viral pathogenesis, mice treated with vSP survived substantially longer when compared with mice treated with the wild-type virus. The mutant virus vSP displayed significant antitumoral effects in an MC38 s.c. tumor model in both nude (P <0.001) and immunocompetent mice (P <0.05). We conclude that this recombinant vaccinia vSP shows promise for oncolytic virus therapy. Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=27544491235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544491235&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1630

DO - 10.1158/0008-5472.CAN-05-1630

M3 - Article

VL - 65

SP - 9991

EP - 9998

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -